drugset / Trial / NCT04124926

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

NCT04124926

Phase 3 Completed 1027 enrolled Phathom Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy and safety of vonoprazan compared to lansoprazole in participants with erosive esophagitis.

Timeline

Start
2019-10-28
Primary completion
2021-07-29
Completion
2021-08-24

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lansoprazole Other / unclassified 15 mg Oral
Comparator Lansoprazole Other / unclassified 30 mg Oral
Subject Vonoprazan Other / unclassified 10 mg Oral
Subject Vonoprazan Other / unclassified 20 mg Oral

Indications